Use of GLP-1 and SGLT2 drugs rises among type 1 diabetes patients in the US

The use of GLP-1 receptor agonists and SGLT2 inhibitors among type 1 diabetes patients has increased significantly from 2010 to 2023, rising from 0.7% to 8.3%. This growth is mainly due to GLP-1 agonists, which are not FDA-approved for this group. Patients prescribed these medications often have additional health issues. For instance, GLP-1 users tend to have higher obesity rates, while SGLT2 users show more kidney and cardiovascular diseases. Concerns about safety and off-label use remain. Research is ongoing to assess the safety of these drugs in type 1 diabetes. The study analyzed data from nearly one million patients, revealing trends in prescribing practices and patient characteristics over the years.